Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be Determined

JAMA Oncol. 2022 Apr 1;8(4):520-521. doi: 10.1001/jamaoncol.2021.6979.
No abstract available

Publication types

  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals* / therapeutic use
  • Drug Approval
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Biosimilar Pharmaceuticals